$RXMD Progressive Care, Inc. (RXMD) Surpasses $32
Post# of 23600
(Total Views: 59)
Posted On: 01/16/2020 6:27:51 AM
$RXMD Progressive Care, Inc. (RXMD) Surpasses $32M in 2019 Sales After Record-Breaking December, Provides Update on Uplisting Process
MIAMI, FL – January 16, 2020 – Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to update current and prospective shareholders with the Company’s operational performance update for the month of December 2019:
· Consolidated monthly gross sales across all locations totaled $3.1 million, representing year-over-year growth of 82% compared to December 2018,
· Prescriptions filled during the month came in at roughly 45,000, representing year-over-year growth of 59% compared to December 2018,
· Third-party billing services for not-for-profit client organizations generated an additional $1 million in total transactions, representing a new Company record,
· December performance brings 2019 sales to a close at $32.25 million (up 54% year-over-year) on more than 450,000 prescriptions filled (up 50% year-over-year), with Family Physicians Rx (FPRX) contributing from June 1 through December 31, 2019.
In addition, the Company has already begun the audit of 2019 financial data for all consolidated operations. The process associated with uplisting Progressive Care shares onto a major US-listed exchange in 2020 continues to move forward. Audited financials will be submitted on or before March 31. The Company will then move to formally file Form S-1 with the US Securities and Exchange Commission during April before submitting an application for uplisting shares to either the Nasdaq or NYSE.
“We closed out 2019 with another month of tremendous growth and execution,” commented S. Parikh Mars, CEO of Progressive Care. “December featured organic same-store growth in our core footprint in both sales and cash flows as well as additional strength from our seamless integration of recently acquired FPRX, which has begun to move the needle on all fronts. If we back the FPRX impact on an annualized basis into 2019, that gives us a baseline of $38 million in annual sales as a point of reference from which to grow in 2020.”
Third-party billing services for not-for-profit clients hit new record levels for the Company in the month of December, reaching the $1 million level in gross billing for the first time ever. The executive team believes this segment represents a strong value add in terms of growth potential and diversification of revenues and will continue to expand independent of the strong growth the Company is already seeing in its core pharmacy operations.
Looking forward, management points to a focus on continued execution, leading to accelerating sales growth and expanding profitability, the completion of fully-audited financials for the 2019 fiscal year, movement toward another value-add acquisition or strategic partnership, and the build-out of the Company’s primary location at 400 Ansin Blvd. in Hallandale Beach, FL, allowing for the full consolidation of operations in 2020.
Mars continued, “The holidays were good to us, thanks in large part to the generous work of our community organizations, the support of our providers and patients, and an unwavering focus by our staff and management to run as tight a ship as possible.”
MIAMI, FL – January 16, 2020 – Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to update current and prospective shareholders with the Company’s operational performance update for the month of December 2019:
· Consolidated monthly gross sales across all locations totaled $3.1 million, representing year-over-year growth of 82% compared to December 2018,
· Prescriptions filled during the month came in at roughly 45,000, representing year-over-year growth of 59% compared to December 2018,
· Third-party billing services for not-for-profit client organizations generated an additional $1 million in total transactions, representing a new Company record,
· December performance brings 2019 sales to a close at $32.25 million (up 54% year-over-year) on more than 450,000 prescriptions filled (up 50% year-over-year), with Family Physicians Rx (FPRX) contributing from June 1 through December 31, 2019.
In addition, the Company has already begun the audit of 2019 financial data for all consolidated operations. The process associated with uplisting Progressive Care shares onto a major US-listed exchange in 2020 continues to move forward. Audited financials will be submitted on or before March 31. The Company will then move to formally file Form S-1 with the US Securities and Exchange Commission during April before submitting an application for uplisting shares to either the Nasdaq or NYSE.
“We closed out 2019 with another month of tremendous growth and execution,” commented S. Parikh Mars, CEO of Progressive Care. “December featured organic same-store growth in our core footprint in both sales and cash flows as well as additional strength from our seamless integration of recently acquired FPRX, which has begun to move the needle on all fronts. If we back the FPRX impact on an annualized basis into 2019, that gives us a baseline of $38 million in annual sales as a point of reference from which to grow in 2020.”
Third-party billing services for not-for-profit clients hit new record levels for the Company in the month of December, reaching the $1 million level in gross billing for the first time ever. The executive team believes this segment represents a strong value add in terms of growth potential and diversification of revenues and will continue to expand independent of the strong growth the Company is already seeing in its core pharmacy operations.
Looking forward, management points to a focus on continued execution, leading to accelerating sales growth and expanding profitability, the completion of fully-audited financials for the 2019 fiscal year, movement toward another value-add acquisition or strategic partnership, and the build-out of the Company’s primary location at 400 Ansin Blvd. in Hallandale Beach, FL, allowing for the full consolidation of operations in 2020.
Mars continued, “The holidays were good to us, thanks in large part to the generous work of our community organizations, the support of our providers and patients, and an unwavering focus by our staff and management to run as tight a ship as possible.”
(0)
(0)Scroll down for more posts ▼